{"id":7667,"date":"2020-02-26T07:22:03","date_gmt":"2020-02-26T07:22:03","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/"},"modified":"2020-02-26T07:22:03","modified_gmt":"2020-02-26T07:22:03","slug":"nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/","title":{"rendered":"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd&rsquo;hui des pr\u00e9sentations \u00e0 des conf\u00e9rences investisseurs, d&rsquo;industrie pharmaceutique et scientifiques en Europe et aux Etats-Unis dans les mois \u00e0 venir.<\/p>\n<h4>CONFERENCES INVESTISSEURS ET D&rsquo;INDUSTRIE PHARMACEUTIQUE<\/h4>\n<p>Des membres de l&rsquo;\u00e9quipe dirigeante de Nicox seront pr\u00e9sents et participeront \u00e0 des rendez-vous individuels aux conf\u00e9rences suivantes :<\/p>\n<ul>\n<li>Oppenheimer 30th Annual Healthcare Conference, 17-18 mars, New York, Etats-Unis<\/li>\n<li>H.C. Wainwright Global Life Sciences Conference, 19-21 avril, Londres, Royaume-Uni<\/li>\n<li>BIO 2020, 8-11 juin, San Diego, Etats-Unis<\/li>\n<\/ul>\n<h4>CONFERENCES SCIENTIFIQUES<\/h4>\n<p>Pr\u00e9sentations \u00e0 des conf\u00e9rences scientifiques majeures dont American Glaucoma Society (AGS), Association for Research in Vision and Ophthalmology (ARVO) et American Society of Cataract and Refractive Surgery (ASCRS)<\/p>\n<p><strong>Informations sur les pr\u00e9sentations (heures locales am\u00e9ricaines) : <\/strong><\/p>\n<p><strong>AGS 2020 Annual Meeting, 27 f\u00e9vrier &#8211; 1er mars 2020, Washington, Etats-Unis<\/strong><\/p>\n<p><strong>Titre<\/strong> : NCX 470, a nitric oxide-donating bimatoprost analog, demonstrates superiority to latanoprost in Phase 2 Dolomites clinical trial (pr\u00e9sentation orale)<br \/>\n<strong>Date<\/strong> : 29 f\u00e9vrier 2020 de 12:03 \u00e0 12:10<br \/>\n<strong>Pr\u00e9sentation<\/strong> : Dr. David Wirta, MD, Aesthetic Eye Care Insititute, CA, Etats-Unis<\/p>\n<p><strong>ARVO 2020 Annual Meeting, 3-7 mai 2020, Baltimore, Etats-Unis.<\/strong><\/p>\n<p><strong>Titre<\/strong> : NCX 470 for IOP lowering: results of the Phase 2 Dolomites trial (pr\u00e9sentation d&rsquo;un poster)<br \/>\n<strong>Date<\/strong> : 6 mai 2020 de 10:15 \u00e0 12:00<br \/>\n<strong>Pr\u00e9sentation<\/strong> : Dr. Tom Walters, MD, Keystone Research Center, PA, Etats-Unis<\/p>\n<p><strong>Titre<\/strong> : Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma (pr\u00e9sentation d&rsquo;une publication)<br \/>\n<strong>Date<\/strong> : 5 mai 2020 de 12:45 \u00e0 13:00<br \/>\n<strong>Pr\u00e9sentation<\/strong> : Francesco Impagnatiello, PhD, Nicox Research Institute<\/p>\n<p><strong>Titre<\/strong> : Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma (pr\u00e9sentation d&rsquo;un poster)<br \/>\n<strong>Date<\/strong> : 4 mai 2020 de 8:15 \u00e0 10:00<br \/>\n<strong>Pr\u00e9sentation<\/strong> : Elena Bastia, PhD, Nicox Research Institute<\/p>\n<p><strong>ASCRS 2020,15-19 mai 2020, Boston, Etats-Unis<\/strong><\/p>\n<p><strong>Titre<\/strong> : Prospective study of NCX 470 for IOP lowering: Phase 2 clinical results (pr\u00e9sentation d&rsquo;un poster)<br \/>\n<strong>Date<\/strong> : 15-19 mai<br \/>\n<strong>Pr\u00e9sentation<\/strong> : Dr. Thomas Walters, MD, Keystone Research Center, PA, U.S., Etats-Unis<\/p>\n<p><strong>Titre<\/strong> : Prospective study of NCX 4251 (fluticasone propionate nanocrystals ophthalmic suspension, 0.1%) for treatment of blepharitis(pr\u00e9sentation d&rsquo;un poster)<br \/>\n<strong>Date<\/strong> : 15-19 mai<br \/>\n<strong>Pr\u00e9sentation<\/strong> : Dr. Gary Foulks, MD, University of Louisville Department of Ophthalmology and Vision Science, KY, Etats-Unis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd&rsquo;hui des pr\u00e9sentations \u00e0 des conf\u00e9rences investisseurs, d&rsquo;industrie pharmaceutique et scientifiques en Europe et aux Etats-Unis dans les mois \u00e0 venir. CONFERENCES INVESTISSEURS ET D&rsquo;INDUSTRIE PHARMACEUTIQUE Des membres de l&rsquo;\u00e9quipe dirigeante de Nicox seront pr\u00e9sents et participeront \u00e0 [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7667","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd&rsquo;hui des pr\u00e9sentations \u00e0 des conf\u00e9rences investisseurs, d&rsquo;industrie pharmaceutique et scientifiques en Europe et aux Etats-Unis dans les mois \u00e0 venir. CONFERENCES INVESTISSEURS ET D&rsquo;INDUSTRIE PHARMACEUTIQUE Des membres de l&rsquo;\u00e9quipe dirigeante de Nicox seront pr\u00e9sents et participeront \u00e0 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-26T07:22:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques\",\"datePublished\":\"2020-02-26T07:22:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\\\/\"},\"wordCount\":405,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\\\/\",\"name\":\"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-02-26T07:22:03+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd&rsquo;hui des pr\u00e9sentations \u00e0 des conf\u00e9rences investisseurs, d&rsquo;industrie pharmaceutique et scientifiques en Europe et aux Etats-Unis dans les mois \u00e0 venir. CONFERENCES INVESTISSEURS ET D&rsquo;INDUSTRIE PHARMACEUTIQUE Des membres de l&rsquo;\u00e9quipe dirigeante de Nicox seront pr\u00e9sents et participeront \u00e0 [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/","og_site_name":"Nicox","article_published_time":"2020-02-26T07:22:03+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/"},"author":{"name":"","@id":""},"headline":"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques","datePublished":"2020-02-26T07:22:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/"},"wordCount":405,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/","url":"https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/","name":"Nicox : Pr\u00e9sentations \u00e0 de prochaines conf\u00e9rences investisseurs, d\u2019industrie pharmaceutique et scientifiques - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-02-26T07:22:03+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-presentations-a-de-prochaines-conferences-investisseurs-dindustrie-pharmaceutique-et-scientifiques\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7667"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7667\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}